Loveday & Co to use Cognetivity’s AI dementia detection technology

ICA test

Technology company Cognetivity Neurosciences will deploy its integrated cognitive assessment (ICA) in Loveday & Co’s Chelsea Court Place to monitor the health of its residents.

The assessment uses artificial intelligence (AI) and machine learning techniques to help detect the earliest signs of impairment by testing the performance of large areas of the brain to support diagnosis of dementia.

Loveday is a dedicated operator of specialist memory care and offers tailored services, including residential support, day clubs, and homecare.

The technology will enable care staff at Loveday to identify when certain interventions may be needed and ensure members receive an appropriate care plan at the earliest possible stage. The ICA can support the whole patient journey, from the screening of at-risk individuals and assessment during the diagnostic process to longer-term monitoring.

Gabriela Zackova, director of wellbeing and dementia at Loveday & Co, said: ‘At Loveday, we believe that our members deserve dignity and a high quality of life regardless of any conditions they are living with. I am confident that Cognetivity’s innovative, industry-leading tool will support us on that mission, and I greatly look forward to seeing it deployed soon.’

Dr Sina Habibi, Cognetivity’s chief executive, said it was exciting to be ‘branching out’ from more traditional assessments in the hospital clinic and into the residential and homecare environments.

‘This is going to be a more and more important area as time goes on, and the fact that the ICA is naturally so well-suited to it means that we can be confident of playing an increasingly large role in the years to come,’ he said.